Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Daiichi Sankyo
H. Lee Moffitt Cancer Center and Research Institute
Daiichi Sankyo
sigma-tau i.f.r. S.p.A.